MedPath
HSA Approval

SUNFLU TABLET

SIN03038P

SUNFLU TABLET

SUNFLU TABLET

June 7, 1989

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

Regulatory Information

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

Therapeutic

Pharmacy Only

Formulation Information

TABLET

**Recommended dosage, dosage schedule and route of administration:** Adults: Two tablets every four hours, not to exceed 8 tablets in 24 hours.

ORAL

Medical Information

**Indications:** It is indicated for the relief of nasal congestion as well as fevers, aches, pains and general discomfort associated with colds and upper respiratory infections.

**Contraindications:** It is contraindicated in patients who are hypersensitive to any of the ingredients. Due to the component phenylephrine, it is contraindicated in patients with ventricular tachycardia or severe hypertension. Due to the component chlorpheniramine maleate, it is contraindicated in patients on monoamine oxidase inhibitor therapy and also in lower respiratory tract infections.

N02BE51

paracetamol, combinations excl. psycholeptics

Manufacturer Information

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

Active Ingredients

PHENYLEPHRINE HCl

5 mg

Phenylephrine

PARACETAMOL

500 mg

Acetaminophen

CAFFEINE

12.5 mg

Caffeine

CHLORPHENIRAMINE MALEATE

2 mg

Chlorpheniramine

Documents

Package Inserts

Sunflu Tablet PI.pdf

Approved: June 21, 2021

Download
© Copyright 2025. All Rights Reserved by MedPath